课题基金 / 基金详情

Study on the molecular diagnosis of metastasis and recurrence and molecular targeted therapy for intractable hepato-pancreatic cancer

Study on the molecular diagnosis of metastasis and recurrence and molecular targeted therapy for intractable hepato-pancreatic cancer
难治性肝胰腺癌转移复发的分子诊断及分子靶向治疗研究
批准号:
20249061
负责人:
ARII Shigeki
金额:
$30.87万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (A)
财政年份:
2008
资助国家:
日本
项目状态:
已结题
起止时间:
2008 至 2011

项目摘要

项目成果

ARII Shigeki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
According to the DNA microarray analysis using clinical samples of hepatocellular carcinoma(HCC), aurora kinase B was identified as the only independent predictor of the lethal recurrence. Preclinical tests revealed the specific inhibitor of aurora kinase B was the promising agent to treat the aggressive HCC.The distinct signature of gene expression closely related to the morphological progression in HCC. Especially, a stem cell marker EpCAM might play a critical role in the aggressiveness of confluent multinodular type of HCC.Among the alterations of transport system in the nuclear microenvironment, we focused on the importin family using microarray analysis of HCC tissues. Importin alpha1 was identified as a molecule activated functionally in HCC cells, and its significance was also validated clinicopathologically.The study showed that(i) tumor-specific hypermethylation-mediated silencing of miR-124 and miR-203 was a relatively frequent molecular event in primary HCCs and(ii) miR-124 and miR-203 exert cell growth-inhibitory effect with the downregulation of their potential targets, resulting in cell cycle arrest at the G1 S checkpoint and apoptosis, respectively.We identified the downregulation of CYP1A2 in non-cancerous liver tissue as a predictive factor for recurrence of early-stage HCC. The significance of non-cancerous CYP1A2 was confirmed by validation study using the prospective multi-center cohort. GSEA revealed that close association of CYP1A2 was implicated with the oxidative stress pathways in liver tissue.We used a fluorescence marker system for level of proteasome activity to identify pancreatic cancer cells with features of cancer stem cells(CSCs). We screened and identified a compound that is specifically toxic to the pancreatic CSCs.
期刊论文(115)
专著(0)
科研奖励(0)
会议论文
パネルディスカッション・外科臨床に基づいた難治性消化器癌の分子標的治療の開発
圆桌讨论/基于外科临床实践开展难治性胃肠癌分子靶向治疗
DOI: --
发表时间: 2010
期刊:
影响因子: --
作者: [大島正充, 辻孝, 川口章, 田中真二,藍原有弘,野口典男,入江工,工藤篤,中村典明,有井滋樹]
通讯作者: 田中真二,藍原有弘,野口典男,入江工,工藤篤,中村典明,有井滋樹
DOI: --
发表时间: 2008
期刊: J Hepatology
影响因子: --
作者: [Hasegawa K, Makuuchi M, TakayamaT, Kokudo N, Arii S, Okazaki M, Okita K, Omata M, Kudo M, Kojiro M, Nakanuma Y, Takayasu K, Monden M, Matsuyama Y, Ikai I]
通讯作者: Ikai I
難治性癌の肝細胞性解析に基づく分子標的治療の開発と応用
基于肝细胞分析的难治性癌症分子靶向治疗的开发与应用
DOI: --
发表时间: 2011
期刊:
影响因子: --
作者: [山本れいこ, ら, 田中真二,村形綾乃,村松俊輔,アディクリスナラマ,茂櫛薫,伴大輔,入江工,野口典男,工藤篤,中村典明,中山恒,田中博,田賀哲也,有井滋樹]
通讯作者: 田中真二,村形綾乃,村松俊輔,アディクリスナラマ,茂櫛薫,伴大輔,入江工,野口典男,工藤篤,中村典明,中山恒,田中博,田賀哲也,有井滋樹
ミニシンポジウム・肝胆膵癌の分子標的治療肝癌臨床検体のオミックス解析を基盤とする分子標的の同定と前臨床試験への展開
小型研讨会:肝胆胰癌分子靶向治疗基于肝癌临床标本组学分析的分子靶点识别及临床前研究进展
DOI: --
发表时间: 2010
期刊:
影响因子: --
作者: [Chiho Takahashi, Hiroyuki Yoshida, Akihiko Komine, Kazuhisa Nakao, Takashi Tsuji, Yasuhiro Tomooka., 田中真二,藍原有弘,伴大輔,野口典男,入江工,工藤篤,中村典明,有井滋樹]
通讯作者: 田中真二,藍原有弘,伴大輔,野口典男,入江工,工藤篤,中村典明,有井滋樹
81
    Multidisciplinary research for molecular mechanism of cancer progression and development of diagnostic and therapeutic tool
    • 批准号:
      18209043
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $32.03万
    • 财政年份:
      2006
    • 负责人:
      ARII Shigeki
    • 依托单位:
    Development of molecular- targeting therapy and prediction of mode of recurrence by analysis of molecular mechanism of invasion and metastasis of hepatocellular carcinoma
    • 批准号:
      16390375
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.15万
    • 财政年份:
      2004
    • 负责人:
      ARII Shigeki
    • 依托单位:
    Order-made medicine for cancer in the viewpoint of angiogenesis
    • 批准号:
      14370379
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.34万
    • 财政年份:
      2002
    • 负责人:
      ARII Shigeki
    • 依托单位:
    Study on the improvement of liver injury by controlling sinusoidal cells and spleen
    海外基金